INJECTIBLE Hypoglycemic Drugs GLP-1 Analogs Exenatide ER Trade Names: Byetta (daily) Bydureon (weekly - extended release) Generic (Nov 2024) Drug Class: DPP-IV resistant Incretin (GLP-1 like) Mimetic Mechanism of Action: a synthetic analog of glucagon-like-polypeptide 1 (GLP-1) that is resistant to breakdown by DPP-IV
GUO: Marta, from the Brookings Institution, she has been watching this battle between the drug companies that invented these products and everyone else trying to get in on the action
The active ingredients involved (semaglutide, tirzepatide) have published clinical-trial results in their FDA-approved forms, detailed above
Cardiovascular events and PsD A meta-analysis of 11 studies reported a 43% increased risk of CV diseases in PsA patients compared to the general population, with elevated risks of myocardial infarction (68%), cerebrovascular disease (22%), and heart failure (31%) [64]
chesty Bodybuilding Competitor #61 You are building very nicely